Stocks · News reference

H.C. Wainwright Maintains Buy Rating and Raises Price Target for Tempus AI

Oct 26, 2026, 6:02 PM

Analyst Yi Chen of H.C. Wainwright maintained a buy rating on Tempus AI and increased the price target from $66 to $68.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 26, 2026, 1:31 PM
Tempus AI Receives IVDR Certification for xR RNA Sequencing Assay
Tempus AI has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) for its xR assay, a Class C in vitro diagnostic device used for solid tumor profiling.
TEM
Fiscal.aiOct 23, 2026, 6:02 PM
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb and Pathos AI
Tempus AI has entered into multi-year agreements with Bristol Myers Squibb and Pathos AI, securing $192.5 million in total cash commitments to support oncology and neurological drug development.
TEM
BenzingaOct 23, 2026, 1:11 PMBenzinga Newsdesk
Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio
BMY TEM